[265 Pages Report] Global Oxytocin market are set to experience a significant growth of 9.0% CAGR from 2022 to 2030, with an estimated market value of around US$ 83.0 Mn as of 2022. As per Future Market Insights’ projections, Postpartum type holds a substantial share of over 88.8% in 2021 within the Global market.

How The Market Progressed Till June 2022?

Report Scope as per Oxytocin Industry Analysis

Abstract: Affectionate touch, which is vital for mental and physical health, was restricted during the Covid-19 pandemic. This study investigated the association between momentary affectionate touch and subjective well-being, as well as salivary oxytocin and cortisol in everyday life during the pandemic. In the first step, we measured anxiety and depression symptoms, loneliness, and attitude toward social touch in a large cross-sectional online survey (N=1,050). From this sample, N=247 participants completed ecologically momentary assessments (EMA) over two days with six daily assessments by answering smartphone-based questions on affectionate touch and momentary mental state and providing concomitant saliva samples for cortisol and oxytocin assessment. Multilevel models showed that on a within-person level, affectionate touch was associated with decreased self-reported anxiety, general burden, stress, and increased oxytocin levels. On a between-person level, affectionate touch was associated with decreased cortisol levels and higher happiness. Moreover, individuals with a positive attitude towards social touch experiencing loneliness reported more mental health problems. Our results suggest that affectionate touch is linked to higher endogenous oxytocin in times of pandemic and lockdown and might buffer stress on a subjective and hormonal level. These findings might have implications for preventing mental burden during social contact restrictions.

The global oxytocin market expansion is anticipated to achieve USD 193.02 million by 2032 exhibiting a CAGR of 9.3% during the forecast period

dataset for Van Cappellen, P., Way, B., Isgett, S. F., & Fredrickson, B. L. (in press). Effects of oxytocin administration on spirituality and emotional responses to meditation. Social Cognitive and Affective Neuroscience.

The table includes 77 products with the active ingredient Oxytocin.

Here you will find data and syntax for analyses in the following manuscript:

Human, L. J., Woolley, J. D., & Mendes, W. B. (in press). Effects of oxytocin on receiving help. Emotion. doi: 10.1037/emo0000369

Abstract: Receiving help can be a “mixed blessing.” Despite the many psychosocial benefits it can carry, it sometimes has negative psychological consequences, such as loss in self-esteem or enhanced guilt. It is, therefore, important to understand the factors that modify responses to receiving help from others. We explored the role of the hormone oxytocin (OT) on affective and social responses to receiving help, given the putative role of OT in social bonding and attunement. To this end, we manipulated whether help was received from a same-sex interaction partner (confederate) versus a control condition, crossed with a double-blind administration of intranasal OT (vs. placebo), and examined subjective and observer-rated participant responses to help. We observed significant interactions between OT and the help manipulation. In the placebo condition, receiving help from the interaction partner compared with the control condition had negative consequences, such that participants reported greater negative affect and came to view themselves and their interaction partners more negatively after interacting together on several tasks. What is important, however, is that OT administration buffered against these negative subjective responses to receiving help. Further, outside observers rated participants who received OT administration as expressing greater happiness and gratitude in response to help, relative to those who received placebo. In sum, in the context of receiving help from a stranger, oxytocin administration fostered more positive affective and social responses.

Market Overview:

The global injection Oxytocin market is expected to grow at a CAGR of 5.5% from 2022 to 2030. The growth in the market can be attributed to the increasing demand for oxytocin for baby born and cosmetic applications, and rising awareness about the benefits of oxytocin therapy. The global injection oxytocin market is segmented by type, application, and region. By type, the market is divided into injection and freeze-dried injection. By application, it is classified into baby born, cosmetic surgery/aesthetics procedures (such as wrinkle removal), labor induction/augmentation (such as speeding up labor), postpartum hemorrhage prevention & treatment (PPH), other applications (including Autism Spectrum Disorder [ASD], cerebral palsy [CP], chronic obstructive pulmonary disease [COPD]). Geographically, it is analyzed across North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Product Definition:

Injection oxytocin is a hormone that is naturally produced by the body. It plays an important role in labor and birth, as well as in breastfeeding. Oxytocin can also be given as a medication to induce labor or to help with breast milk production.

Injection:

Injection oxytocin is a hormone that is produced in the hypothalamus and released into the bloodstream. It is sometimes called "the love hormone" because it helps to create feelings of trust, affection, and security. Injection oxytocin is used to treat conditions such as labor pains, postpartum depression, and autism.

Freeze-dried Injection:

Freeze-dried Injection oxytocin is a form of oxytocin that is freeze-dried. It is used to treat baby born, for domestic, and for others. It provides long-term stability and is easy to administer. It is made from pure oxytocin and has the same effects as oxytocin that is injected.

Application Insights:

For baby born was the largest application segment in the global market and accounted for over 60% of total revenue in 2015. A rise in the number of female reproductive organ donors is expected to boost demand for this drug, which is used as a labor-inducing agent during childbirth. In addition, growing awareness among women regarding pain management during pregnancy will also drive demand over the forecast period. The freeze-dried injection is anticipated to be the fastest growing application segment with a CAGR of around 12% from 2022 to 2030 owing to advantages such as fewer needle pricks and faster absorption by vein compared with other forms of injections. Owing to the increase in adoption rates across various countries including India, China, Japan, Brazil, etc., this drug has become an important tool for treating domestic animals such as horses and dogs along with humans which further boosts its consumption globally.

Regional Analysis:

North America dominated the global market in terms of revenue share in 2019. The region is expected to continue its dominance over the forecast period owing to increasing R&D activities and rising awareness about new technologies for safe delivery. In addition, the presence of key players with extensive research & development capabilities is also likely to support regional growth. Asia Pacific market was valued at USD X million in 2019 and is anticipated to witness lucrative CAGR over the forecast period due to the growing population, improving healthcare infrastructure along with high unmet medical needs, especially regarding premature birth complications are some factors driving regional growth. In Latin America, Oxytocin Injection has been approved by regulatory agencies as a part of national public health programs aimed at reducing the infant mortality rate (IMR).

Growth Factors:

• Increasing demand from pregnant women for the prevention of post-partum hemorrhage.
• Rising prevalence of gynecological disorders such as uterine fibroids, endometriosis, and ovarian cysts.
• Growing awareness about the benefits of oxytocin injection in childbirth and labor induction.
• An increasing number of clinical studies support the use of oxytocin injection in various medical applications.
• Technological advancements have led to the development of new and improved formulations.

Report Scope

Get the sample copy of Oxytocin Market Report 2024 (Global Edition) which includes data such as Market Size, Share, Growth, CAGR, Forecast, Revenue, list of Oxytocin Companies (Merck & Co, Pfizer, Mylan, GSK, Novartis, Roche, Grindeks), Market Segmented by Type (Oxytocin Injection, Dry Powder Oxytocin), by Application (For Baby Born, For Comestic, Others)

The global oxytocin market is expected to reach a CAGR of 7.1%. The growth of this market is mainly driven by the increasing demand for oxytocin across different applications such as labor induction and augmentation, postpartum hemorrhage treatment, dairy cattle farming, and others.

Oxytocin is a hormone that occurs naturally in the body. It plays a role in childbirth, breastfeeding, and orgasm. Oxytocin also helps to start and continue labor contractions during labor and delivery.

On the basis of types, the market is segmented into injection and nasal spray.

Injection:

An injection is a method of administering medication or other fluid substances directly into the bloodstream, tissue, or organ. Injection therapy involves the direct introduction of an agent (such as a drug) into the circulatory system through a vein in the arm, often via an intravenous drip.

Nasal Spray:

A nasal spray is a device that delivers medication to the nose in a fine mist. The medication gets into the body through the membranes in the nose. Nasal sprays are often used to treat congestion, allergies, and other respiratory problems. Some nasal sprays can also be used as contraceptives.

On the basis of Application, the market is segmented into For Baby Born, For Comestic.

For Baby Born:

Oxytocin is used to induce labor in pregnant women who have reached full term. It is also given to speed up labor that has started spontaneously but is progressing slowly. Oxytocin may be used if the baby seems to be in distress or if the woman’s water has broken but she has not gone into labor.

For Comestic:

Oxytocin is a medication used to facilitate childbirth and reduce bleeding after delivery. It also has other uses, such as inducing sexual arousal in men, increasing milk production in women, speeding up labor, and alleviating postpartum depression symptoms. Oxytocin is administered through an injection or nasal spray.

On the basis of region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

North America is the largest market for oxytocin due to the high demand from various applications such as labor induction and augmentation, postpartum hemorrhage treatment, dairy cattle farming, and others. Latin America is anticipated to grow at a significant rate during the forecast period due to the high penetration of oxytocin in clinical practice, and raising awareness about its benefits. Europe is the second-largest market for oxytocin. The market is driven by the increasing demand from different applications such as labor induction and augmentation, postpartum hemorrhage treatment, dairy cattle farming, and others.

The Asia Pacific is expected to grow at a high rate during the forecast period owing to the increase in population, rising awareness about the benefits of oxytocin therapy, and growing investments by key players in this region. The Middle East & Africa is projected to be the fastest-growing market for oxytocin during the forecast period. This growth can be attributed to factors such as an increase in research and development activities, a rising geriatric population, and growing demand for oxytocin across different applications.

Growth Factors of the Oxytocin Market:

Oxytocin is used to induce labor in pregnant women who have reached full term. It is also given to speed up labor that has started spontaneously but is progressing slowly. Oxytocin may be used if the baby seems to be in distress or if the woman’s water has broken but she has not gone into labor.

Report Scope

Global Oxytocin Market was valued at USD 1.25 billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.72% through 2029.

Contact: Dr. Natalie Ebner (natalie.ebner@ufl.edu)

Please see the following a preprint for the Data in Brief manuscript associated with this dataset: https://osf.io/wn7sj/

Overview

Single Dose Intranasal Oxytocin Administration: Data from Healthy Younger and Older Adults This study examined the effects of a single-dose (24 international units) intranasal OT vs. PL administration on brain and behavioral outcomes in younger (n = 44; aged 18-31 years; 48% female) and older (n = 43; aged 63-81 years; 56% female) adults. The study followed a 2 (age: Younger, Older) X 2 (sex: Male, Female) X 2 (treatment: OT, PL) design.

Data was collected between August 2013 and October 2014. Potential participants were first prescreened for study eligibility over the phone (~30 min), during which they completed the Telephone Interview for Cognitive Status (Brandt, Specter, & Folstein, 1988) and self-reported demographic information. Eligible participants then came to the University of Florida for an in-person screening session (~45 min) during which they completed cognitive tests (Digit Symbol Substitution Test, Weschler, 1981; Rey Auditory Verbal Learning Test, Rey, 1964) as well as provided blood and saliva samples. Participants then returned for an in-person full session (~3 hrs) during which they self-administered the intranasal spray (OT or PL; randomized, double-blind procedure) and underwent a T1-weighted (T1w) structural scan along with a resting-state fMRI scan. Neuroimaging data were collected on a 3T Philips Achieva MRI Scanner at the UF McKnight Brain Institute.

Subjects

Generally healthy younger (n = 44; aged 18-31 years; 48% female) and older (n = 43; aged 63-81 years; 56% female) adults were recruited from the Gainesville, FL area. No participant had neurological or psychiatric disorders, and all participants were able to understand and give informed written consent for this study. All older participants scored ≥ 30 on the Telephone Interview For Cognitive Status (Brandt, Specter, & Folstein, 1988). Only white, English-speaking adults were included in this study. All older women included in the study were postmenopausal whereas all younger women were premenopausal. Individuals with contraindications for MRI or intranasal OT spray self-administration were excluded for safety. Individuals with certain metal implants or pacemakers; who were pregnant or breastfeeding; excessively smoked or drank alcohol; and/or had severe or progressive medical illness(es) were not eligible for this study. Participants were debriefed and compensated at the end of the study.

Apparatus

A 3T Philips Achieva MRI Scanner with a 32-channel head coil was used to acquire brain images. Participants were placed in the MRI scanner with their heads comfortably positioned and stabilized with cushions to reduce head motion.

Task details

Following recommendations for the standardized administration of intranasal OT (Guastella et al., 2013), participants self-administered 24 IU (i.e., one puff per nostril) of OT or PL, which contained the same ingredients as the OT spray except for the synthetic OT (IND 100,860). Compounding, dispensing, and randomization were overseen by the dispensing pharmacy.

Before MRI scanning, participants received instructions about the MRI procedure as well as an overview of the experimental tasks they would complete inside the scanner. Participants were settled into the 3T MRI scanner ~45 minutes after self-administration of OT or PL. Participants underwent anatomical image acquisition followed by functional image acquisition across four tasks (not included in this dataset), including an eyes-open resting-state scan.

Anatomical data was collected in the first 10 minutes of the MRI scanning for anatomical details. These anatomical scans included a high-resolution three-dimensional T1w scan using an MP-RAGE sequence (sagittal plane, TR/TE/TI = 7/3.2/2750 ms, flip angle = 8°; in-plane FOV = 240 mm x 240 mm; imaging matrix 240 x 240; 170 contiguous sagittal slices with 1 mm slice thickness, 1x1x1 mm3 isotropic voxels).

For functional scans, a single-shot gradient echo, echo-planar imaging sequence sensitized to blood oxygenation level-dependent (BOLD) contrast (TR = 2000 ms, TE = 30 ms, flip angle = 90°, in-plane FOV = 240 mm x 240 mm, 80x80 matrix size, 3x3x3 mm3 isotropic voxels, 38 interleaved axial slices (ascending 1, 3, 5, etc.), zero inter-slice gap) was used for whole-brain fMRI coverage. Every functional run started with 4 dummy scans (each lasting 1 TR (2000ms) which is 8 seconds); each run ended with a “fade out” period of 4 dummy scans (each lasting 1 TR (2000ms) which is 8 seconds). The resting-state scan took place between 70–90 minutes after spray administration and lasted about 8 minutes with 240 time points acquired. Participants lay supine and were instructed to relax and look at a white fixation cross on a black screen.

Additional data acquired

This study comprised 1) an initial phone prescreening call to determine study eligibility (~30 min), 2) an in-person screening session (~45 min), and 3) an in-person full MRI session (~3 hrs; see task details above). Only the acquisition of measures provided in this dataset is described here.

1. Prescreening call

During an initial phone prescreening, older participants underwent the Telephone Interview for Cognitive Status to screen for cognitive decline (Brandt, Spencer, & Fosltein, 1988). All participants completed an MRI Eligibility Form and a study-specific Health Screening and Demographics Form to assess demographic information, present health conditions, and health history. Based on these measures, eligibility for the study was determined. Eligible participants were then scheduled for an in-person screening session and full session on campus. All participants provided informed written consent before enrollment . All in-person sessions took place at ~8:00 AM. Participants were also instructed to stay hydrated and abstain from substance use and caffeine for 24 hours and from food, exercise, and sexual activity for at least two hours before the sessions.

1. In-person screening session

During the in-person screening session, participants completed an intake interview and cognitive measures that included the Rey Auditory Verbal Learning task (RAVLT; Rey, 1964), which measures short-term verbal memory, and the Digit Symbol Substitution Test (DSST; Wechsler, 1981), which measures sensorimotor processing speed, among other questionnaires. For female participants, menstrual cycle phase data was also obtained via self-report.

Saliva (i.e., ApoE status) and blood sampling (i.e., plasma OT and AVP levels) were conducted along with a health review by a clinician. Saliva samples were collected using the OraGene DNA Self Collection Kit OG-500 (http://www.dnagenotek.com/ROW/products/OG500.html); participants salivated approximately 2mL into a collection tube that is part of the kit. Saliva samples were assayed by the Translational Genomics Research Institute (PI: Huentelman) between February and April 2022. Blood plasma was frozen to –70 °C directly after collection and only thawed immediately before assay. OT (unextracted) and AVP were measured via Enzyme Immunoassay (EIA), purchased from Enzo Life Sciences, Inc. (Farmingdale, New York); plasma samples were run at the same time with inter- and intra-assay coefficients of variation less than 8%.

1. In-person full MRI session

Participants eligible for full study participation returned to campus at a later date for the in-person full session. During this session, participants underwent further MRI safety determination and completed another intake interview. See task details above for more information.

Experimental location

Participants were recruited around the Gainesville area in Florida, USA (GPS coordinates: 29.6446° N, 82.3535° W) and attended study sessions at the University of Florida. Sessions were conducted in the Department of Psychology, the Institute on Aging, and the McKnight Brain Institute at the University of Florida between August 2013 to October 2014.

Missing data

Some data was not included in this repository due to technical issues (resulting in missing or corrupted files) as well as study attrition. Several participants did not complete the resting-state functional scan, which was the last scan in the imaging sequence, due to time restrictions (e.g., technical difficulties earlier on in the session, late arrival of participant) and thus are not included in this dataset. Any missing phenotype data are designated with “n/a” (i.e., not applicable) in the dataset.

Notes

Two subjects (sub-11001 and sub-12000) had slightly different resting state scan parameters from the rest of the participants. Participant specific JSON resting state files are in the /func directories for these participants, while the JSON files at the root directory apply to all other participants.

Endogenous oxytocin predicts helping and conversation as a function of group membership

G protein-coupled receptors (GPCRs) constitute a vast protein family that encompasses a wide range of functions, including various autocrine, paracrine and endocrine processes. They show considerable diversity at the sequence level, on the basis of which they can be separated into distinct groups . The term clan can be used to describe the GPCRs, as they embrace a group of families for which there are indications of evolutionary relationship, but between which there is no statistically significant similarity in sequence . The currently known clan members include rhodopsin-like GPCRs (Class A, GPCRA), secretin-like GPCRs (Class B, GPCRB), metabotropic glutamate receptor family (Class C, GPCRC), fungal mating pheromone receptors (Class D, GPCRD), cAMP receptors (Class E, GPCRE) and frizzled/smoothened (Class F, GPCRF) . GPCRs are major drug targets, and are consequently the subject of considerable research interest. It has been reported that the repertoire of GPCRs for endogenous ligands consists of approximately 400 receptors in humans and mice . Most GPCRs are identified on the basis of their DNA sequences, rather than the ligand they bind, those that are unmatched to known natural ligands are designated by as orphan GPCRs, or unclassified GPCRs .

Injection Oxytocin Sales Market is expected to increase at a CAGR of 3 to 5 percent, from its estimated valuation of USD XX Million by 2031

The global Oxytocin receptor antagonists market is expected to grow from USD 9.2 million in 2021 to USD X.X million by 2028, at a CAGR of 7.0%. The growth of this market can be attributed to the increasing prevalence of various diseases, rising demand for better treatment options, and growing awareness about available treatment options.

Oxytocin receptor antagonists are drugs that block the action of the hormone oxytocin. Oxytocin is a hormone that is involved in childbirth and breastfeeding, and also plays a role in social bonding. Oxytocin receptor antagonists can be used to treat conditions such as uterine bleeding, overactive uterus, and premature labor.

On the basis of types, the market is segmented into Non-Peptide and Orally Active Oxytocin Receptor Antagonist, High Affinity Human Oxytocin (OT) Receptor Antagonist.

Non-Peptide and Orally Active Oxytocin Receptor Antagonist

Non-peptide and orally active oxytocin receptor antagonists (OTA) are drugs that bind to and block oxytocin receptors. Oxytocin is a hormone involved in social bonding, sexual reproduction, and mother-infant interaction. By blocking the action of oxytocin, OTA can be used to treat conditions like anxiety, Autism Spectrum Disorder (ASD), postpartum depression (PPD), and premenstrual dysphoric disorder (PMDD). OTA is typically given as a pill or injection. They work quickly and have few side effects. The most common side effect is temporary gastrointestinal upset.

High Affinity Human Oxytocin (OT) Receptor Antagonist

High Affinity Human Oxytocin (OT) Receptor Antagonist is a drug that blocks the action of oxytocin. Oxytocin is a hormone that is released during labor and breastfeeding, and it has many other functions in the body. High Affinity Human Oxytocin (OT) Receptor Antagonist prevents oxytocin from binding to its receptors, which prevents it from having its effects. Oxytocin receptor antagonists are used to treat conditions such as uterine bleeding, preterm labor, and postpartum hemorrhage. They are also being studied for their potential use in treating autism spectrum disorder and social anxiety disorder.

On the basis of Application, the market is segmented into Animals, People.

Animals

The first use of oxytocin receptor antagonists was in animals for obstetric indications. Oxytocin is a naturally occurring hormone that helps with parturition (delivery) by causing smooth muscle contractions in the uterus. It also causes the release of milk from the mammary glands and the contraction of smooth muscles in the gastrointestinal tract, which aids in expelling the placenta. Oxytocin receptor antagonists work by binding to oxytocin receptors and blocking their action. This results in a decrease in uterine contractions, which can delay or prevent parturition. Oxytocin receptor antagonists have also been used for other indications such as reducing preoperative stress and anxiety in animals, as well as decreasing intraoperative blood loss.

People

In people, oxytocin antagonists are being investigated as potential treatments for social anxiety disorder, autism spectrum disorders, and schizophrenia. Oxytocin has been shown to be involved in social cognition and its deficits are thought to underlie the social deficits seen in these disorders. A number of clinical trials are currently underway investigating the use of oxytocin receptor antagonists in these conditions.

On the basis of region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

North America is projected to grow at a higher rate owing to the presence of key players in this region and raising awareness about the therapeutic benefits of oxytocin receptor antagonists.

Latin America is expected to grow at a moderate rate over the forecast period.

In Europe, oxytocin receptor antagonists are gaining popularity as a therapeutic option for various indications such as autism spectrum disorder and social anxiety disorder.

The Asia Pacific is anticipated to be the fastest-growing region owing to the increasing availability of oxytocin receptor antagonists and raising awareness of their therapeutic benefits.

Growth factors of the Oxytocin Receptor Antagonists Market

Some of the key factors driving the growth of the oxytocin receptor antagonist market include the rising prevalence of autism spectrum disorder, social anxiety disorder, and other indications. In addition, the increasing availability of oxytocin receptor antagonists and raising awar

The Global Oxytocin Receptor Antagonists Market is projected to grow from USD 7.4 Million in 2021 to reach a value of USD XX Million by 2028, at a CAGR of 5% during the forecast period. The major factors driving the growth of this market are the increasing number of women with postpartum depression and the high prevalence rate for autism spectrum disorder (ASD) among children globally.

Oxytocin receptor antagonists are a class of drugs that compete with and prevent the binding of endogenous, naturally occurring oxytocin to its receptors. Oxytocin is a hormone responsible for social bonding in mammals; thus, blocking its activity at specific neuroreceptors may be beneficial to relieve some types of psychological stress like anxiety or depressive disorders.

On the basis of Type, Global Oxytocin Receptor Antagonists Market is segmented into Non-Peptide and Orally Active Oxytocin Receptor Antagonist, High-Affinity Human Oxytocin (OT) Receptor Antagonist.

Non-Peptide and Orally Active Oxytocin Receptor Antagonist:

Non-Peptide and Orally Active Oxytocin Receptor Antagonist is a type of oxytocin receptor antagonist that blocks the activity of OT receptors. It works by preventing the action of endogenous (occurring naturally within an organism) or exogenous (introduced to an organism from outside) hormones at their site of action, thus disrupting endocrine system function.

High-Affinity Human Oxytocin (OT) Receptor Antagonist:

High-Affinity Human OT receptor antagonists are a class of drugs that compete with and prevent the binding of endogenous, naturally occurring oxytocin to its receptors. In this way, they block the activity of other agents at their site of action.

On the basis of Application, Global Oxytocin Receptor Antagonists Market is segmented into Animals, People.

People:

The people segment includes research of oxytocin receptor antagonists that focus on the treatment and management of anxiety disorders, such as generalized anxiety disorder (GAD), postpartum depression (PPD), or social phobia. This market is expected to grow at a higher CAGR during the forecast period.

Animals:

This market covers studies related to oxytocin receptor antagonists for use in companion animals, livestock, and laboratory animal species. It also focuses on pet behavioral problems like separation distress syndrome or noise aversion syndrome.

On the basis of Region, Global Oxytocin Receptor Antagonists Market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa.

North America: The U.S., Canada, and Mexico are the major countries in North America; therefore, this region has been covered under one section. The growth of the oxytocin receptor antagonists market is mainly driven by rising cases of autism spectrum disorder (ASD) among children aged less than five years due to a high prevalence rate across North America.

Latin America: The countries included under Latin America are Argentina, Chile, Colombia, Mexico, and others. The oxytocin receptor antagonists market in this region is expected to grow at a higher CAGR during the forecast period due to the high incidence of autism among children aged less than five years compared with other regions across Latin America.

Europe: Europe includes Germany, France, Spain UK, and several other European nations as well as their neighboring countries like Turkey & Israel that affect the growth of oxytocin receptor antagonists market significantly by influencing trade activities throughout Europe. In addition to this factor, increasing cases of anxiety disorders such as GAD or PPD contribute towards the growth of this regional oxytocin marketspace from 2021-2028.

Asia Pacific: Asia-Pacific countries include China, South Korea, Japan, Thailand, and other emerging economies. The oxytocin receptor antagonists market in this region is expected to grow at a higher CAGR during the forecast period due to increasing cases of stress or anxiety disorders among children aged less than five years coupled with rising disposable income levels across these nations.

The Middle East & Africa: Countries included under the Middle East are Saudi Arabia, UAE, Egypt, and Israel while Bahrain Lebanon Qatar has been covered under African Marketspace for Oxytocin Receptor Antagonists Market report 2021-2028. The growth of this regional marketspace is mainly driven by factors such as the high prevalence rate of autism spectrum disorder (ASD) among children aged less than five years, which is three to six ti

Approximately 10% of trauma-exposed individuals go on to develop post-traumatic stress disorder (PTSD). Neural emotion regulation may be etiologically involved in PTSD development. Oxytocin administration early post-trauma may be a promising avenue for PTSD prevention, as intranasal oxytocin has previously been found to affect emotion regulation networks in healthy individuals and psychiatric patients. In a randomized double-blind placebo-controlled between-subjects functional magnetic resonance (fMRI) study, we assessed the effects of a single intranasal oxytocin administration (40 IU) on seed-based amygdala resting-state FC with emotion regulation areas (ventromedial prefrontal cortex (vmPFC), ventrolateral prefrontal cortex (vlPFC)), and salience processing areas (insula, dorsal anterior cingulate cortex (dACC)) in 37 individuals within 11 days post trauma. Two resting-state scans were acquired; one after neutral- and one after trauma-script-driven imagery. We found that oxytocin administration reduced amygdala-left vlPFC FC after trauma script-driven imagery, compared with neutral script-driven imagery, whereas in PL-treated participants enhanced amygdala-left vlPFC FC was observed following trauma script-driven imagery. Irrespective of script condition, oxytocin increased amygdala-insula FC and decreased amygdala-vmPFC FC. These neural effects were accompanied by lower levels of sleepiness and higher flashback intensity in the oxytocin group after the trauma script. Together, our findings show that oxytocin administration may impede emotion regulation network functioning in response to trauma reminders in recently trauma-exposed individuals. Therefore, caution may be warranted in administering oxytocin to prevent PTSD in distressed, recently trauma-exposed individuals.

An analysis of the statistical power of oxytocin administration studies. See the Wiki for a description of the project files

Social behavior plays an essential role in daily life. The neuropeptide oxytocin has generated considerable interest for its role in social behavior and potential to treat psychiatric disorders characterised by social dysfunction. This study advances our understanding of the neurobiological substrates of social behavior by interrogating human whole-brain maps of oxytocin pathway gene expression, demonstrating these genes are enriched in central, temporal, and olfactory brain regions. We also show via large-scale fMRI meta-analysis that these gene expression patterns correspond with brain regions involved in emotion and motivation processing. These results provide a proof-of-principle demonstration of corresponding mental states with gene expression patterns of a neuropeptide pathway involved in complex human behaviors, and identify neural network targets for future oxytocin trials.

3890 Global exporters importers export import shipment records of Oxytocin injection with prices, volume & current Buyer's suppliers relationships based on actual Global export trade database.